ストックスクリーナーアプリを入手
8.20
4.24%
0.41
前日終値:
$7.79
開ける：
$7.78
24時間の取引高:
39,633
Relative Volume:
0.49
時価総額：
$188.74M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+15.67%
1か月 パフォーマンス:
+21.74%
6か月 パフォーマンス:
+6.01%
1年 パフォーマンス:
+10.48%
1日の値動き範囲:
$7.78
$8.3037
1週間の範囲:
$6.87
$8.49
52週間の値動き範囲:
$5.47
$11.99
Actuate Therapeutics Inc Stock (ACTU) Company Profile
ACTU を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
8.12 | 181.07M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.60 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.79 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.54 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.70 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.41 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-26 | 開始されました | B. Riley Securities | Buy |
| 2025-04-22 | 開始されました | Craig Hallum | Buy |
| 2025-03-17 | 開始されました | H.C. Wainwright | Buy |
Actuate Therapeutics Inc (ACTU) 最新ニュース
Using Bollinger Bands to evaluate Actuate Therapeutics Inc.Trade Volume Summary & Long-Term Growth Portfolio Plans - newser.com
Actuate Therapeutics Inc. stock retracement – recovery analysisWeekly Trend Report & Entry Point Strategy Guides - newser.com
Heatmap analysis for Actuate Therapeutics Inc. and competitorsSell Signal & Safe Entry Trade Reports - newser.com
How to forecast Actuate Therapeutics Inc. trends using time series2025 Earnings Surprises & Technical Buy Zone Confirmations - newser.com
Risk vs reward if holding onto Actuate Therapeutics Inc.Dollar Strength & Real-Time Market Trend Scan - newser.com
How hedge fund analytics apply to Actuate Therapeutics Inc. stock2025 Market Sentiment & Free High Accuracy Swing Entry Alerts - newser.com
Will Actuate Therapeutics Inc. stock see insider buyingPortfolio Risk Report & Fast Exit and Entry Trade Guides - newser.com
Can Actuate Therapeutics Inc. stock deliver sustainable ROETrade Exit Summary & Low Risk Profit Maximizing Plans - newser.com
Reversal indicators forming on Actuate Therapeutics Inc. stock2025 Valuation Update & Daily Chart Pattern Signal Reports - newser.com
Myelofibrosis Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros - Barchart.com
Actuate Therapeutics (NASDAQ:ACTU) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
Applying Elliott Wave Theory to Actuate Therapeutics Inc.2025 Momentum Check & Expert Curated Trade Ideas - newser.com
Price action breakdown for Actuate Therapeutics Inc.Market Volume Report & Growth Focused Investment Plans - newser.com
Is Actuate Therapeutics Inc. trending in predictive chart models2025 Big Picture & Free Daily Entry Point Trade Alerts - newser.com
Evaluating Actuate Therapeutics Inc. with trendline analysisJuly 2025 Patterns & Weekly Top Gainers Trade List - newser.com
How to build a custom watchlist for Actuate Therapeutics Inc.2025 Top Decliners & AI Based Buy and Sell Signals - newser.com
Is Actuate Therapeutics Inc. forming a reversal patternWeekly Earnings Recap & Low Risk Investment Opportunities - newser.com
Craig-Hallum Maintains Actuate Therapeutics(ACTU.US) With Buy Rating - 富途牛牛
H.C. Wainwright Maintains Actuate Therapeutics(ACTU.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛
B.Riley Financial Initiates Actuate Therapeutics(ACTU.US) With Buy Rating, Announces Target Price $20 - 富途牛牛
Pancreatic Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Bio, Keymed Biosciences, Carisma Therapeu - Barchart.com
Relative strength of Actuate Therapeutics Inc. in sector analysisPortfolio Return Report & AI Enhanced Execution Alerts - newser.com
Published on: 2025-10-02 23:42:39 - newser.com
Ataxia Telangiectasia Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight - openPR.com
Actuate Therapeutics Inc Stock Analysis and ForecastHigh Beta Stocks & Budget Friendly Investment Plans - earlytimes.in
Goldman Sachs Group Inc. Has $151,000 Holdings in Actuate Therapeutics, Inc. $ACTU - Defense World
Myelofibrosis Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - Barchart.com
Myelofibrosis Market Outlook 2034Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - openPR.com
Published on: 2025-09-29 03:19:58 - newser.com
What analysts say about Actuate Therapeutics Inc stockShort-Term Trading Alerts & Trade Like a Pro Using AI Edge - Early Times
Actuate Therapeutics Inc (ACTU) 財務データ
Actuate Therapeutics Inc (ACTU) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Actuate Therapeutics Inc (ACTU) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Kreis Leslie W. | Director |
Jun 27 '25 |
Buy |
7.00 |
71,428 |
499,996 |
196,428 |
| Fletcher Aaron G.L. | Director |
Jun 27 '25 |
Buy |
7.00 |
71,428 |
499,996 |
196,428 |
1.24%
大文字化:
|
ボリューム (24 時間):